Cargando…

Pembrolizumab

The development of the cytotoxic T-lymphocyte-associated protein 4 inhibitor ipilimumab and its approval in 2011 for the treatment of metastatic melanoma has heralded a new era in immuno-oncology. Subsequently, novel agents against the programmed death receptor 1 (PD-1)/programmed death receptor lig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khoja, Leila, Butler, Marcus O., Kang, S. Peter, Ebbinghaus, Scot, Joshua, Anthony M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539882/ https://www.ncbi.nlm.nih.gov/pubmed/26288737 http://dx.doi.org/10.1186/s40425-015-0078-9

Ejemplares similares

Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices
por: Cowey, C. Lance, et al.
Publicado: (2018)

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006
por: Hamid, Omid, et al.
Publicado: (2018)

Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors
por: Ayers, Mark, et al.
Publicado: (2015)

AR Signaling and the PI3K Pathway in Prostate Cancer
por: Crumbaker, Megan, et al.
Publicado: (2017)

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
por: Dummer, Reinhard, et al.
Publicado: (2015)

Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC)
por: Hodi, F Stephen, et al.
Publicado: (2014)

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program
por: Gangadhar, Tara C., et al.
Publicado: (2017)

Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients
por: Khoja, Leila, et al.
Publicado: (2016)

The full blood count as a biomarker of outcome and toxicity in ipilimumab‐treated cutaneous metastatic melanoma
por: Khoja, Leila, et al.
Publicado: (2016)

Molecular Farming of Pembrolizumab and Nivolumab
por: Stark, Michael C., et al.
Publicado: (2023)

Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma
por: Manusow, Joshua S, et al.
Publicado: (2014)

Spotlight on pembrolizumab in the treatment of advanced melanoma
por: Rajakulendran, Thanashan, et al.
Publicado: (2015)

Challenging the standard of care in advanced melanoma: focus on pembrolizumab
por: Abdul-Karim, Raghad M, et al.
Publicado: (2017)

Pembrolizumab for all
por: Kim, Myung S., et al.
Publicado: (2022)

Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
por: Wang, Meihua, et al.
Publicado: (2019)

New developments in the management of advanced melanoma – role of pembrolizumab
por: Improta, Giuseppina, et al.
Publicado: (2015)

Pembrolizumab in cervical cancer: latest evidence and clinical usefulness
por: Borcoman, Edith, et al.
Publicado: (2017)

Pembrolizumab in endometrial cancer: Where we stand now
por: Aravantinou-Fatorou, Aikaterini, et al.
Publicado: (2021)

Efficacy of Pembrolizumab in Advanced Melanoma: A Narrative Review
por: Rizzetto, Giulio, et al.
Publicado: (2023)

Targeted Treatment of Advanced Endometrial Cancer: Focus on Pembrolizumab
por: El-ghazzi, Nathan, et al.
Publicado: (2023)

Pembrolizumab: First in Class for Treatment of Metastatic Melanoma
por: Barnhart, Carrie
Publicado: (2015)

Combined use of pembrolizumab and lenvatinib: A review
por: Eisinger, Casey, et al.
Publicado: (2023)

Readministration of Pembrolizumab after Treatment of Tuberculosis Activated by Initial Pembrolizumab Therapy
por: Murakami, Shuji, et al.
Publicado: (2020)

Pembrolizumab-Induced Cold Agglutinin Disease
por: Atiq, Osman, et al.
Publicado: (2020)

Pembrolizumab microgravity crystallization experimentation
por: Reichert, Paul, et al.
Publicado: (2019)

Assessment of a prognostic model, PSA metrics and toxicities in metastatic castrate resistant prostate cancer using data from Project Data Sphere (PDS)
por: Pitcher, Bethany, et al.
Publicado: (2017)

Pembrolizumab‐induced sarcoid granulomatous panniculitis and bullous pemphigoid in a single patient
por: Honigman, Anthony D., et al.
Publicado: (2019)

Into the Clinic With Nivolumab and Pembrolizumab
por: Shu, Catherine A., et al.
Publicado: (2016)

Pembrolizumab-associated sarcoidosis
por: Cotliar, Jonathan, et al.
Publicado: (2016)

Pembrolizumab-induced pneumonitis
por: Leroy, Vincent, et al.
Publicado: (2017)

Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer
por: Mimura, Kaito, et al.
Publicado: (2022)

New developments in the management of head and neck cancer – impact of pembrolizumab
por: Saleh, Khalil, et al.
Publicado: (2018)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
por: Inokuchi, Junichi, et al.
Publicado: (2019)

Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
por: Boyiadzis, Michael M., et al.
Publicado: (2018)

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer
por: Zhang, Tian, et al.
Publicado: (2020)

Biomarkers predictive of response to pembrolizumab in head and neck cancer
por: Pfister, David G., et al.
Publicado: (2022)

Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report
por: Song, Haa-Na, et al.
Publicado: (2018)

Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date
por: Vachhani, Pankit, et al.
Publicado: (2016)

Autoimmune Diabetes Associated With Pembrolizumab: A Review of Published Case Reports
por: Cheema, Anmol, et al.
Publicado: (2018)

Potential of Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer: Evidence to Date
por: McCusker, Michael G, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p0j63vc2r7labudrm36th051p0